Risk of Intraepithelial Neoplasia Grade 3 or Worse (CIN3+) Among Women Examined by a 5-Type HPV MRNA Test During 2003 and 2004, Followed Through 2015

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 28

PMID 37370716

Authors

Amir Rad

Sveinung Wergeland Sorbye

Sweta Tiwari

Maja-Lisa Lochen

Finn Egil Skjeldestad

Affiliations

Soon will be listed here.

Abstract

Background: The study's purpose was to evaluate the performance of a five-type HPV mRNA test to predict cervical intraepithelial neoplasia grade 3 or worse (CIN3+) during up to 12 years of follow-up.

Methods: Overall, 19,153 women were recruited by gynecologists and general practitioners in different parts of Norway between 2003 and 2004. The study population comprised 9582 women of these women, aged 25-69 years with normal cytology and a valid five-type HPV mRNA test at baseline. Follow-up for CIN3+ through 2015 was conducted in the Norwegian Cervical Cancer Screening Programme.

Results: The cumulative incidence of CIN3+ by baseline status for HPV mRNA-positive and mRNA-negative women were 20.8% and 1.1%, respectively ( < 0.001). Age did not affect the long-term ability of the HPV mRNA test to predict CIN3+ during follow-up.

Conclusion: The low long-term risk of CIN3+ among HPV mRNA-negative women and the high long-term risk among HPV mRNA-positive women strengthen the evidence that the five-type HPV mRNA test is an appropriate screening test for women of all ages. Our findings suggest that women with a negative result may extend the screening interval up to 10 years.

Citing Articles

High rate of persistent HPV detection after diagnostic cervical excision in older screen-positive women.

Gustafson L, Krog L, Sardini B, Tranberg M, Petersen L, Andersen B Acta Obstet Gynecol Scand. 2025; 104(2):342-349.

PMID: 39745094 PMC: 11782055. DOI: 10.1111/aogs.15019.

Enhancing Cervical Cancer Screening with 7-Type HPV mRNA E6/E7 Testing on Self-Collected Samples: Multicentric Insights from Mexico.

Flores C, Falang B, Gomez-Laguna L, Gutierrez G, Leon J, Uribe M Cancers (Basel). 2024; 16(13).

PMID: 39001547 PMC: 11240307. DOI: 10.3390/cancers16132485.

References

Powell N, Hibbitts S, Boyde A, Newcombe R, Tristram A, Fiander A . The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer. 2010; 128(7):1676-82. DOI: 10.1002/ijc.25485. View

Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S . The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2012; 132(1):101-8. DOI: 10.1002/ijc.27636. View

Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson B . HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007; 97(1):129-32. PMC: 2359659. DOI: 10.1038/sj.bjc.6603843. View

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P . Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2010; 49(2):557-64. PMC: 3043526. DOI: 10.1128/JCM.02147-10. View

Arbyn M, Tommasino M, Depuydt C, Dillner J . Are 20 human papillomavirus types causing cervical cancer?. J Pathol. 2014; 234(4):431-5. DOI: 10.1002/path.4424. View

Kraus I, Molden T, Holm R, Lie A, Karlsen F, Kristensen G . Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006; 44(4):1310-7. PMC: 1448674. DOI: 10.1128/JCM.44.4.1310-1317.2006. View

Arbyn M, Snijders P, Meijer C, Berkhof J, Cuschieri K, Kocjan B . Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin Microbiol Infect. 2015; 21(9):817-26. DOI: 10.1016/j.cmi.2015.04.015. View

Sundstrom K, Dillner J . How Many Human Papillomavirus Types Do We Need to Screen For?. J Infect Dis. 2020; 223(9):1510-1511. DOI: 10.1093/infdis/jiaa587. View

Woodman C, Collins S, Young L . The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2006; 7(1):11-22. DOI: 10.1038/nrc2050. View

10.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A . Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11(3):249-57. DOI: 10.1016/S1470-2045(09)70360-2. View

11.

Cuschieri K, Cubie H, Whitley M, Gilkison G, Arends M, Graham C . Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005; 58(9):946-50. PMC: 1770812. DOI: 10.1136/jcp.2004.022863. View

12.

Rad A, Sorbye S, Brenn T, Tiwari S, Lochen M, Skjeldestad F . 13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25-33 Years with Minor Cytological Abnormalities-6 Years of Follow-Up. Int J Environ Res Public Health. 2023; 20(5). PMC: 10002392. DOI: 10.3390/ijerph20054119. View

13.

Reinholdt K, Juul K, Dehlendorff C, Munk C, Kjaer S, Thomsen L . Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study. Acta Obstet Gynecol Scand. 2019; 99(2):204-212. DOI: 10.1111/aogs.13741. View

14.

Moberg M, Gustavsson I, Wilander E, Gyllensten U . High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer. 2005; 92(5):891-4. PMC: 2361906. DOI: 10.1038/sj.bjc.6602436. View

15.

Kjaer S, Frederiksen K, Munk C, Iftner T . Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102(19):1478-88. PMC: 2950170. DOI: 10.1093/jnci/djq356. View

16.

Katki H, Kinney W, Fetterman B, Lorey T, Poitras N, Cheung L . Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12(7):663-72. PMC: 3272857. DOI: 10.1016/S1470-2045(11)70145-0. View

17.

Castle P, Rodriguez A, Burk R, Herrero R, Wacholder S, Alfaro M . Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009; 339:b2569. PMC: 2718087. DOI: 10.1136/bmj.b2569. View

18.

Khan M, Castle P, Lorincz A, Wacholder S, Sherman M, Scott D . The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97(14):1072-9. DOI: 10.1093/jnci/dji187. View

19.

Riibe M, Sorbye S, Simonsen G, Sundsfjord A, Ekgren J, Maltau J . Risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) among women with HPV-test in 1990-1992, a 30-year follow-up study. Infect Agent Cancer. 2021; 16(1):46. PMC: 8220730. DOI: 10.1186/s13027-021-00386-z. View

20.

Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L . Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013; 108(4):908-13. PMC: 3590662. DOI: 10.1038/bjc.2013.22. View